Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

Single inhaled treatment produced significant reductions in symptoms within 24 hours, but effects were not sustained at one week.

While the CDC report is delayed, non-government researchers are tracking trends in real time. A December 9 report from #WeCount, sponsored by the Society of Family Planning, found that abortions in ...

Congenital HI is a rare genetic condition that results in persistent hypoglycemia due to the overproduction of insulin. Ersodetug, a fully human monoclonal antibody, binds allosterically to insulin ...

Pegcetacoplan yields significantly greater change in proteinuria than placebo in C3 glomerulopathy or primary immune-complex MPGN.

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.